Vaxart Q4 2023 Earnings Report $0.72 -0.03 (-3.74%) As of 01/29/2025 04:00 PM Eastern Earnings HistoryForecast Vaxart EPS ResultsActual EPS-$0.12Consensus EPS -$0.15Beat/MissBeat by +$0.03One Year Ago EPSN/AVaxart Revenue ResultsActual Revenue$3.25 millionExpected Revenue$0.45 millionBeat/MissBeat by +$2.80 millionYoY Revenue GrowthN/AVaxart Announcement DetailsQuarterQ4 2023Date3/14/2024TimeN/AConference Call ResourcesConference CallConference Call TranscriptPress ReleaseVXRT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Vaxart Earnings HeadlinesVaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of DirectorsJanuary 28 at 5:37 PM | markets.businessinsider.comVaxart appoints Kevin Finney to board of directorsJanuary 28 at 5:37 PM | markets.businessinsider.comAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.January 30, 2025 | Altimetry (Ad)Vaxart (NASDAQ: VXRT) Receives Positive Recommendation for Phase 2b COVID-19 Vaccine TrialOn January 13, 2025, Vaxart, Inc. announced that an independent Data Safety Monitoring Board has recommended that the Company's Phase 2b clinical trial evaluatiJanuary 23, 2025 | americanbankingnews.comVaxart highlights progress of COVID-19, norovirus, influenza programsJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review To Continue COVID-19 Phase 2b Trial; Stock UpJanuary 14, 2025 | markets.businessinsider.comSee More Vaxart Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxart? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxart and other key companies, straight to your email. Email Address About VaxartVaxart (NASDAQ:VXRT), a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.View Vaxart ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Apple (1/30/2025)Comcast (1/30/2025)Intel (1/30/2025)KLA (1/30/2025)Sanofi (1/30/2025)Atlassian (1/30/2025)Arthur J. Gallagher & Co. (1/30/2025)Caterpillar (1/30/2025)The Cigna Group (1/30/2025)Canadian National Railway (1/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
